PFIZER INC Inventory Write-down
PFIZER INC (PFE) reported Inventory Write-down of $46.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-04
- PFIZER INC inventory write-down for the quarter ending 2026-06-28 was $46.00M.
- PFIZER INC inventory write-down for the quarter ending 2025-12-31 was -$33.00M.
- PFIZER INC inventory write-down for the quarter ending 2025-09-28 was $33.00M.
- PFIZER INC inventory write-down for the quarter ending 2025-06-29 was $0.00.
- PFIZER INC inventory write-down for fiscal 2025 was $0.00.
- PFIZER INC inventory write-down for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- PFIZER INC inventory write-down for fiscal 2023 was $6.20B, a 424.01% increase from fiscal 2022.
- PFIZER INC inventory write-down for fiscal 2022 was $1.18B.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-28 | $46.00M 10-Q · filed 2026-08-04 | $46.00M 10-Q · filed 2026-08-04 | ||
| 2025-12-31 | -$33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-28 | $33.00M 10-Q · filed 2025-11-04 | $33.00M derived: sum of 2 quarters · filed 2026-08-04 | $33.00M 10-Q · filed 2025-11-04 | |
| 2025-06-29 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-29 | $0.00 10-Q · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $352.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.20B 10-K · filed 2026-02-26 | ||
| 2023-10-01 | $5.85B 10-Q · filed 2024-11-04 | |||
| 2022-12-31 | $707.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.18B 10-K · filed 2025-02-27 | ||
| 2022-10-02 | $476.00M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2010-10-03 | $212.00M 10-K · filed 2011-02-28 | $212.00M 10-Q · filed 2010-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |